| INDUSTRY NEWS | Landmark Ruling Comes into Effect: Treatment Now Available for People in England and Wales With Mild Alzheimer’s At Time of Diagnosis Eisai Co., Ltd. announced that new Alzheimer’s disease treatment guidance issued by the United Kingdom’s National Institute for Health and Clinical Excellence (NICE) came into effect on March 23, 2011 (U.K. local time), marking a significant change to an earlier 2007 ruling which restricted access to medication for patients with moderate disease only. [Eisai Co., Ltd. Press Release] Yuma Therapeutics Awarded a Research Grant by the Alzheimer’s Drug Discovery Foundation to Develop Novel Therapeutics for Alzheimer’s Disease The Alzheimer’s Drug Discovery Foundation (ADDF) announced that it has awarded a grant of $249,810 to Yuma Therapeutics Corporation to develop small molecules to treat Alzheimer’s disease. [Therapeutics Daily] Prize for Research on Multiple Sclerosis Goes to Lawrence Steinman Lawrence Steinman, MD, the George A. Zimmerman Professor of Neurology and Neurological Sciences, will receive the 2011 Multiple Sclerosis International Federation Charcot Award, a biennial award that recognizes a lifetime achievement in research into the understanding or treatment of multiple sclerosis. [Stanford University School of Medicine Press Release] Neuroscience Groups Alarmed as Pharma Bolts Brain Drug R&D Facing an unusually high risk of failure at the same time investors are demanding that Big Pharma show them the new products, a slate of European companies has dropped out or scaled back work in neuroscience. [FierceBiotech] Neurologix Announces Year End 2010 Results Neurologix, Inc., a biotechnology company engaged in the development of innovative gene therapies for disorders of the brain and central nervous system, announced its financial results for the year ended December 31, 2010. [Neurologix, Inc. Press Release] Canadian Budget Targets Brain Research, But Critics See Political Motives A private foundation’s brain research initiative would receive significant government support in a new budget unveiled yesterday by Canada’s minority Conservative Party. But that approach to research is exactly what’s wrong with the 2011-2012 budget, say its critics: New investments are reserved for large, targeted ventures with political clout, while investigator-driven basic science continues to be squeezed. [ScienceInsider] Alzheimer’s Drug Discovery Foundation Supports ADispell Technology with a Grant to Advance Novel Drug Candidates for Alzheimer’s Disease The Alzheimer’s Drug Discovery Foundation (ADDF) announced that it has awarded a grant of $170,750 to ADispell Inc. to develop small molecule drugs designed to halt the progression of cognition loss that occurs with Alzheimer’s Disease. [ADispell Inc. Press Release] |
|
|
|